Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Impella 2.5 System (Abiomed Inc.) for cardiac support in patients undergoing high-risk percutaneous coronary intervention. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem:
Patients undergoing percutaneous coronary intervention (PCI) may be considered high risk based on a variety of factors, including advanced age, comorbidities, and lesion-specific characteristics. Patients undergoing high-risk PCI (HRPCI) may require mechanical circulatory support (MCS) during the PCI procedure to prevent adverse events and improve clinical outcomes.
Technology Description: The Impella 2.5 is an intravascular, nonpulsatile axial blood pump indicated for temporary use during HRPCI. It is inserted percutaneously, usually through the femoral artery, and threaded into the left ventricle, where it pumps blood into the aorta at a rate of up to 2.5 liters per minute. Controversy: Controversies revolve around agreement on the definition of HRPCI and the lack of determinative risk scores for MCS support during HRPCI.
Key Questions:
For adults undergoing HRPCI, is the Impella 2.5 MCS efficacious in improving post-procedure outcomes? How does the Impella 2.5 MCS compare with other clinical alternatives (e.g., medical management, IABP, and other MCS) for adults undergoing HRPCI? Is the Impella 2.5 MCS safe in adults undergoing HRPCI? Have definitive patient selection criteria been identified for the Impella 2.5 MCS in patients undergoing HRPCI? Indexing Status Subject indexing assigned by CRD MeSH Heart; Humans; Percutaneous Coronary Intervention; Risk Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32018000071 Date abstract record published 14/02/2018 |